315 related articles for article (PubMed ID: 37477841)
1. Systemic Lupus Erythematosus and COVID-19.
Pappa M; Panagiotopoulos A; Thomas K; Fanouriakis A
Curr Rheumatol Rep; 2023 Oct; 25(10):192-203. PubMed ID: 37477841
[TBL] [Abstract][Full Text] [Related]
2. Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study.
Jiang X; Sparks J; Wallace Z; Deng X; Li H; Lu N; Xie D; Wang Y; Zeng C; Lei G; Wei J; Zhang Y
RMD Open; 2023 Mar; 9(1):. PubMed ID: 36889799
[TBL] [Abstract][Full Text] [Related]
3. Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management.
Mehta P; Gasparyan AY; Zimba O; Kitas GD
Clin Rheumatol; 2022 Sep; 41(9):2893-2910. PubMed ID: 35639259
[TBL] [Abstract][Full Text] [Related]
4. Attitudes towards and safety of the SARS-CoV-2 inactivated vaccines in 188 patients with systemic lupus erythematosus: a post-vaccination cross-sectional survey.
Tang Q; Li F; Tian J; Kang J; He J
Clin Exp Med; 2023 Jun; 23(2):457-463. PubMed ID: 35612692
[TBL] [Abstract][Full Text] [Related]
5. Effect of Systemic Lupus Erythematosus and Immunosuppressive Agents on COVID-19 Vaccination Antibody Response.
Petri M; Joyce D; Haag K; Fava A; Goldman DW; Zhong D; Xiao S; Milstone A; Magder LS
Arthritis Care Res (Hoboken); 2023 Sep; 75(9):1878-1885. PubMed ID: 36714913
[TBL] [Abstract][Full Text] [Related]
6. Lupus, vaccinations and COVID-19: What we know now.
Mason A; Anver H; Lwin M; Holroyd C; Faust SN; Edwards CJ
Lupus; 2021 Sep; 30(10):1541-1552. PubMed ID: 34134555
[TBL] [Abstract][Full Text] [Related]
7. Short- and mid-term outcomes in systemic lupus erythematosus patients presenting with disease exacerbation after SARS-CoV-2 mRNA vaccination: A cohort study from Puerto Rico.
González-Meléndez A; Báez-Negrón L; Ríos-Rivera R; Franco-O'Connell AS; Nieves-Plaza M; Vilá LM
Lupus; 2023 Apr; 32(4):571-579. PubMed ID: 36639887
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 vaccination in systemic lupus erythematosus: a systematic review of its effectiveness, immunogenicity, flares and acceptance.
Tan SYS; Yee AM; Sim JJL; Lim CC
Rheumatology (Oxford); 2023 May; 62(5):1757-1772. PubMed ID: 36271852
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series.
Assawasaksakul T; Sathitratanacheewin S; Vichaiwattana P; Wanlapakorn N; Poovorawan Y; Kittanamongkolchai W
RMD Open; 2021 Dec; 7(3):. PubMed ID: 34862313
[TBL] [Abstract][Full Text] [Related]
10. The Use of COVID-19 Vaccines in Patients with SLE.
Tang W; Gartshteyn Y; Ricker E; Inzerillo S; Murray S; Khalili L; Askanase A
Curr Rheumatol Rep; 2021 Nov; 23(11):79. PubMed ID: 34767100
[TBL] [Abstract][Full Text] [Related]
11. Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus.
Mok CC; Chan KL; Tse SM
Vaccine; 2022 Sep; 40(41):5959-5964. PubMed ID: 36085256
[TBL] [Abstract][Full Text] [Related]
12. Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis.
Wang P; Ni J; Chu YY; Chen QQ; Wu GC; Fang Y; Chen C; Zhang RD; Jiang LQ; Zhao Y; Fang X; He J; Wang DG; Wang GH; Pan HF
Biomed Pharmacother; 2022 Jun; 150():112997. PubMed ID: 35486976
[TBL] [Abstract][Full Text] [Related]
13. Clinical features of newly diagnosed systemic lupus erythematosus after SARS-CoV-2 vaccination.
Moriyama M; Noda K; Ito H; Matsushita T; Kurosaka D
Mod Rheumatol Case Rep; 2023 Dec; 8(1):63-68. PubMed ID: 37348045
[TBL] [Abstract][Full Text] [Related]
14. Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
He F; Luo Q; Lei M; Fan L; Shao X; Hu K; Qin S; Yu N; Cao J; Yang L
Clin Rheumatol; 2020 Sep; 39(9):2803-2810. PubMed ID: 32725351
[TBL] [Abstract][Full Text] [Related]
15. Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus.
Yoshida T; Tsuji H; Onishi A; Takase Y; Shirakashi M; Onizawa H; Hiwa R; Kitagori K; Akizuki S; Nakashima R; Tanaka M; Yoshifuji H; Morinobu A
Lupus Sci Med; 2022 Aug; 9(1):. PubMed ID: 35961691
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 vaccine-triggered conversion from systemic lupus erythematosus (SLE) to bullous SLE and dipeptidyl peptidase 4 inhibitors-associated bullous pemphigoid.
Nakahara Y; Yamane M; Sunada M; Aoyama Y
J Dermatol; 2023 Feb; 50(2):162-165. PubMed ID: 36578130
[TBL] [Abstract][Full Text] [Related]
17. Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year.
Ramirez GA; Argolini LM; Bellocchi C; Moroni L; Della-Torre E; Farina N; Caporali RF; Beretta L; Gerosa M; Bozzolo EP; Dagna L;
Clin Immunol; 2021 Oct; 231():108845. PubMed ID: 34478882
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study.
Naveen R; Nikiphorou E; Joshi M; Sen P; Lindblom J; Agarwal V; Lilleker JB; Tan AL; Salim B; Ziade N; Velikova T; Gracia-Ramos AE; Kuwana M; Day J; Makol A; Distler O; Chinoy H; Traboco LS; Wibowo SAK; Tehozol EAZ; Serrano JR; García-De La Torre I; ; Aggarwal R; Gupta L; Agarwal V; Parodis I
Rheumatology (Oxford); 2023 Jul; 62(7):2453-2463. PubMed ID: 36413073
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and risk of disease flare after a three-dose regimen with SARS-CoV-2 vaccination in patients with systemic lupus erythematosus: results from the prospective cohort study COVAC-SLE.
Larsen ES; Nilsson AC; Möller S; Voss AB; Johansen IS
Clin Exp Rheumatol; 2023 Mar; 41(3):676-684. PubMed ID: 35894059
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 and Systemic Lupus Erythematosus.
Thanou A; Sawalha AH
Curr Rheumatol Rep; 2021 Jan; 23(2):8. PubMed ID: 33511495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
